Hallmarks of the Tumour Microenvironment of Gliomas and Its Interaction with Emerging Immunotherapy Modalities

Article Oncology

Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial

Antonio Omuro et al.

Summary: This study showed that TMZ + RT had better efficacy than NIVO + RT in newly diagnosed GBM patients with unmethylated MGMT promoter. However, no new safety signals were detected with NIVO in this study.

NEURO-ONCOLOGY (2023)

Add to Collection

Article Oncology

Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma A Phase 3 Prospective Externally Controlled Cohort Trial

Linda M. Liau et al.

Summary: The study shows that adding autologous tumor lysate-loaded dendritic cell vaccine (DCVax L) to standard of care can extend the survival of patients with glioblastoma.

JAMA ONCOLOGY (2023)

Add to Collection

Review Biotechnology & Applied Microbiology

Oncolytic virus therapy for malignant gliomas: entering the new era

Hirotaka Fudaba et al.

Summary: Oncolytic viruses (OVs) are innovative therapeutic approach for treating malignant brain tumors, featuring unique mechanisms of action. The recent conditional approval of oncolytic herpes simplex virus G47 Delta as a therapeutic for malignant brain tumors is a significant milestone in the field of neuro-oncology.

EXPERT OPINION ON BIOLOGICAL THERAPY (2023)

Add to Collection

Article Biotechnology & Applied Microbiology

CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma

Guoqing Wang et al.

Summary: Glioblastoma (GBM) is a highly aggressive primary malignant brain cancer that requires effective treatment. Chimeric antigen receptor T (CAR-T) cell therapy shows potential, but its efficacy is hindered by poor infiltration of CAR-T cells in tumors and an immunosuppressive tumor microenvironment (TME). This study demonstrates that arming an oncolytic adenovirus (oAds) with CXCL11 increases CAR-T cell infiltration and reprograms the immunosuppressive TME, thus improving therapeutic efficacy.

MOLECULAR THERAPY (2023)

Add to Collection

Review Microbiology

HPV and Cervical Cancer: A Review of Epidemiology and Screening Uptake in the UK

Sunyoung Choi et al.

Summary: Cervical cancer is a common malignancy in females worldwide and a leading cause of death in the UK, with HPV being the strongest risk factor. The UK has implemented successful national HPV immunisation and cytology-based cervical cancer screening services. However, there has been a decline in age-appropriate coverage since 2010 and the COVID-19 pandemic disrupted screening and immunisation programmes. Socioeconomic factors and lifestyle choices also contribute to the incidence of cervical cancer. This article provides an update on cervical cancer epidemiology, HPV pathogenesis and transmission, and prevention programmes in the NHS.

PATHOGENS (2023)

Add to Collection

Review Oncology

Mechanisms driving the immunoregulatory function of cancer cells

Antoinette van Weverwijk et al.

Summary: Tumours exhibit a wide range of variations in the distribution, composition, and activation state of immune cells, which affect their progression and response to immunotherapy. Understanding the mechanisms that regulate the diversity and function of immune cells in the tumour microenvironment will lead to the development of more targeted immunomodulatory strategies for the benefit of cancer patients.

NATURE REVIEWS CANCER (2023)

Add to Collection

Review Biotechnology & Applied Microbiology

Engineered cells as glioblastoma therapeutics

Aparna Ramanathan et al.

Summary: Engineered cell therapies for glioblastoma have shown feasibility and safety in clinical trials, with some evidence of activity. Various starting cell types for engineered cell therapies have their own strengths and weaknesses. The future direction is to continue exploring and optimizing this promising modality for glioblastoma therapy.

CANCER GENE THERAPY (2022)

Add to Collection

Review Immunology

CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future

Ya-Jui Lin et al.

Summary: Chimeric antigen receptor T (CAR T) cell therapy has shown remarkable clinical effects in treating hematological malignancies, leading to interest in developing therapies for solid tumors, including brain tumors. However, CAR T cell therapy against brain tumors has been limited by antigen heterogeneity, difficulty in tumor site trafficking, and the immunosuppressive tumor microenvironment. This review discusses current CAR T cell approaches for cancer treatment, with a particular focus on brain cancers. A novel technique using focused ultrasound to control the activation of engineered CAR T cells is also described to achieve safer cell therapies. Additionally, combinational strategies are discussed to improve the efficacy of CAR T cell therapy and overcome historical limitations.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Oncology

Enhancement of CD70-specific CAR T treatment by IFN-γ released from oHSV-1-infected glioblastoma

Guidong Zhu et al.

Summary: Despite progressive combination treatments, the prognosis for glioblastoma (GBM) patients remains poor. Oncolytic viruses (OVs) have emerged as a promising therapeutic strategy for GBM by stimulating immune cells and enhancing tumor microenvironment (TME) through the release of cytokines like IFN-gamma. The study shows that oncolytic herpes simplex virus-1 (oHSV-1) enhances the antitumor efficacy of novel CD70-specific chimeric antigen receptor (CAR) T cells by promoting T cell infiltration and IFN-gamma release, supporting the use of CAR T therapy in GBM treatment strategies.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

Add to Collection

Review Pharmacology & Pharmacy

Pharmacological targeting of the tumor-immune symbiosis in glioblastoma

Lizhi Pang et al.

Summary: Glioblastoma (GBM) is a common and lethal brain tumor, and the symbiotic interaction between immune cells and GBM cells plays a critical role in tumor progression and therapy resistance. Targeting the tumor-immune symbiosis pharmacologically has emerged as a promising strategy for GBM treatment.

TRENDS IN PHARMACOLOGICAL SCIENCES (2022)

Add to Collection

Review Cell & Tissue Engineering

Hurdles to breakthrough in CAR T cell therapy of solid tumors

Faroogh Marofi et al.

Summary: CAR T cell therapy has emerged as a promising treatment option for hematological malignancies, particularly B cell malignancies. However, its effectiveness in solid tumors is hindered by various complications, such as the immunosuppressive tumor microenvironment, tumor antigen heterogeneity, and limited accessibility to tumor cells. Strategies have been recommended to overcome these challenges and enhance the performance of infused T cells.

STEM CELL RESEARCH & THERAPY (2022)

Add to Collection

Review Immunology

The Global Impact of Hepatitis B Vaccination on Hepatocellular Carcinoma

Joan Ericka Flores et al.

Summary: Hepatitis B vaccination remains crucial for preventing liver cancer and achieving global hepatitis B elimination targets, but there is variability in vaccination coverage and challenges in meeting the targets.

VACCINES (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Intratumoral oncolytic herpes virus G47 increment for residual or recurrent glioblastoma: a phase 2 trial

Tomoki Todo et al.

Summary: A crucial clinical trial demonstrates that repeated tumor-administration of oncolytic herpes virus G47 Increment in residual or recurrent glioblastoma leads to improved survival rates and a safe profile.

NATURE MEDICINE (2022)

Add to Collection

Article Pharmacology & Pharmacy

Microsatellite instability testing in colorectal patients with Lynch syndrome: lessons learned from a case report and how to avoid such pitfalls

Sola Adeleke et al.

Summary: We present a case study of a patient with Lynch syndrome and metastatic colorectal carcinoma (mCRC). The initial immunohistochemistry (IHC) test for mismatch repair deficiency yielded incorrect results, but subsequent testing confirmed the presence of microsatellite instability (MSI). The patient responded positively to immunotherapy, highlighting the importance of accurate testing strategies to guide therapy in mCRC. We advocate for the use of both IHC and MSI-PCR tests and the need for a better understanding of their limitations.

PERSONALIZED MEDICINE (2022)

Add to Collection

Article Multidisciplinary Sciences

Spatiotemporal analysis of glioma heterogeneity reveals COL1A1 as an actionable target to disrupt tumor progression

Andrea Comba et al.

Summary: This study investigates the dynamic anatomical structures called oncostreams in high grade gliomas (HGG) and their regulation by COL1A1. The researchers found that oncostreams play a role in tumor growth and aggression, facilitating the distribution of tumor and non-tumor cells within the tumor and potentially contributing to the invasion of normal brain tissue. They also discovered that COL1A1 is a central gene in the organization of oncostreams and a powerful regulator of glioma malignant behavior. Inhibiting COL1A1 can eliminate oncostreams and alter the tumor microenvironment, leading to reduced expression of mesenchymal associated genes and extended survival in animal models.

NATURE COMMUNICATIONS (2022)

Add to Collection

Review Immunology

Advanced Cell Therapies for Glioblastoma

Guangwen Wang et al.

Summary: GBM is a highly treatment-resistant tumor with a poor prognosis, and it has proven to be resistant to both traditional and newer immunotherapies. The need for innovative and efficient treatment strategies is urgent. This review provides a comprehensive overview of various cell therapies currently being used to treat GBM, discussing their efficacy, safety, mechanisms, and challenges, with the aim of identifying the next-generation immunotherapeutic approach to eliminate this dreadful disease.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Review Neurosciences

Glioblastoma microenvironment and its reprogramming by oncolytic virotherapy

Zhongbing Qi et al.

Summary: Glioblastoma is a highly aggressive form of brain tumor that responds poorly to conventional therapies. Oncolytic virus therapy shows promise in improving therapeutic efficacy, but limitations as a monotherapy need to be overcome.

FRONTIERS IN CELLULAR NEUROSCIENCE (2022)

Add to Collection

Article Oncology

Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47? combination therapy against glioblastoma

Lushun Chalise et al.

Summary: Lp2-CAR-T cells specifically target PDPN-expressing tumor cells and demonstrate selective cytotoxicity. Combination therapy with G47D further inhibits glioblastoma growth and improves survival.

MOLECULAR THERAPY-ONCOLYTICS (2022)

Add to Collection

Article Endocrinology & Metabolism

Myeloid-derived itaconate suppresses cytotoxic CD8+ T cells and promotes tumour growth

Hongyun Zhao et al.

Summary: This study reveals that itaconate, produced by myeloid-derived suppressor cells (MDSCs), acts as an immune checkpoint metabolite to suppress CD8(+) T cells. Inhibition of IRG1 may enhance anti-tumour immunity and improve the efficacy of immune checkpoint blockade. These findings have implications for understanding immune surveillance and developing new strategies for cancer treatment.

NATURE METABOLISM (2022)

Add to Collection

Review Oncology

Cancer vaccines: the next immunotherapy frontier

Matthew J. Lin et al.

Summary: The article discusses the current status and potential of cancer vaccines, emphasizing the need for accurate immune monitoring of early trials to advance the most promising vaccines. It also classifies cancer vaccines based on the included antigens and their colocalization with antigen-presenting cells, highlighting the challenges and opportunities in advancing these vaccines to the clinic.

NATURE CANCER (2022)

Add to Collection

Review Oncology

Immune Checkpoint Inhibitors in Cancer Therapy

Yavar Shiravand et al.

Summary: The discovery of immune checkpoint proteins has revolutionized cancer immunotherapy, leading to the successful utilization of targeted monoclonal antibodies in various cancer patients. However, not all patients respond favorably to these drugs, emphasizing the need for biomarkers to predict treatment responses.

CURRENT ONCOLOGY (2022)

Add to Collection

Review Oncology

Immune suppression in gliomas

Matthew M. Grabowski et al.

Summary: Gliomas evade immune detection and destruction through mechanisms such as dysfunctional T cells and NK cells, expansion of regulatory T cells and myeloid-derived suppressor cells, M2 phenotypic transformation in macrophages/microglia, upregulation of immunosuppressive factors, tumor microenvironment hypoxia, and iatrogenic effects of immunosuppressive treatments. Future research should focus on addressing these immunosuppressive mechanisms to develop treatment options with improved survival outcomes.

JOURNAL OF NEURO-ONCOLOGY (2021)

Add to Collection

Review Oncology

Melanoma of unknown primary: New perspectives for an old story

Stergios Boussios et al.

Summary: Melanoma of unknown primary site (MUP) accounts for 3-4% of all melanomas and presents mostly in lymph nodes, subcutaneous sites, and visceral organs. MUP and stage-matched melanoma of known primary site (MKP) share similar prognostic factors, but treatment outcomes vary.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)

Add to Collection

Article Oncology

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018

Quinn T. Ostrom et al.

Summary: The report from CBTRUS provides the most up-to-date population-based data on primary brain tumors in the United States, including incidence rates, mortality rates, and survival rates for both malignant and non-malignant tumors.

NEURO-ONCOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Autologous adoptive immune-cell therapy elicited a durable response with enhanced immune reaction signatures in patients with recurrent glioblastoma: An open label, phase I/IIa trial

Jaejoon Lim et al.

Summary: The study investigated the safety and efficacy of adoptive immune-cell therapy for recurrent GBM patients, demonstrating the therapy's safety and effectiveness in patients with high immune response signatures. The median overall survival was 22.5 months, with a median progression-free survival of 10 months.

PLOS ONE (2021)

Add to Collection

Review Oncology

Immunosuppression in Gliomas via PD-1/PD-L1 Axis and Adenosine Pathway

Thamiris Becker Scheffel et al.

Summary: Glioblastoma is a highly malignant subtype of glioma, and the immune landscape within the tumor microenvironment plays a crucial role in influencing therapy outcomes. The presence of multiple immunosuppression pathways, particularly the adenosine pathway, poses significant obstacles to immune-based cancer therapies and can contribute to treatment resistance. Research focusing on immune checkpoints and the adenosine pathway may provide insights into potential targets for improving tumor treatment strategies.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

An Oncolytic Virus Expressing IL15/IL15Rα Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma

Rui Ma et al.

Summary: The study demonstrated that the combination therapy of an oncolytic virus expressing the IL15/IL15Rα complex and off-the-shelf EGFR-CAR NK cells elicited strong antitumor responses in glioblastoma. This therapy significantly inhibited tumor growth and improved survival rates, offering a promising strategy for the clinical management of this devastating disease.

CANCER RESEARCH (2021)

Add to Collection

Review Oncology

Enhancing T Cell Chemotaxis and Infiltration in Glioblastoma

Kirit Singh et al.

Summary: Glioblastoma is an immunologically 'cold' tumor characterized by low or absent numbers of tumor-infiltrating lymphocytes, which if present are exhausted and ineffective. To maximize immunotherapy efficacy in glioblastoma, it is highly desirable to enhance the trafficking of lymphocytes to the tumor. However, the process of T cell recruitment into the central nervous system is tightly regulated, involving multiple steps including interaction with the blood-brain barrier and navigating the tumor microenvironment.

CANCERS (2021)

Add to Collection

Review Oncology

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

David N. Louis et al.

Summary: The fifth edition of the WHO Classification of Tumors of the Central Nervous System integrates molecular diagnostics into CNS tumor classification, introduces different approaches to tumor nomenclature and grading, and emphasizes the importance of integrated diagnoses and layered reports.

NEURO-ONCOLOGY (2021)

Add to Collection

Review Medicine, General & Internal

Current knowledge on the immune microenvironment and emerging immunotherapies in diffuse midline glioma

Gabrielle Price et al.

Summary: Diffuse midline glioma (DMG) is an incurable malignancy with the highest mortality rate among pediatric brain tumors. The tumor microenvironment of DMG consists of a largely immunologically cold environment lacking immune cell infiltration, immunosuppressive factors, and immune surveillance.

EBIOMEDICINE (2021)

Add to Collection

Review Cell Biology

The Interplay between Glioblastoma and Its Microenvironment

Mark Dapash et al.

Summary: GBM, the most common primary brain tumor in adults, has poor prognosis due to its aggressive nature; treatments, including immunotherapies, are hindered by the complex interactions within the tumor microenvironment; understanding and manipulating the different components and pressures in the TME can lead to more targeted therapies and potentially improved patient outcomes.

CELLS (2021)

Add to Collection

Review Medicine, General & Internal

Unraveling the Wide Spectrum of Melanoma Biomarkers

Antonios Revythis et al.

Summary: The use of biomarkers in medicine is crucial for diagnosis, prognostication, and prediction of treatment response. With advancements in understanding DNA mutational profiles, new gene targets and proteins are being identified. Currently, only a small number of available biomarkers are being utilized, but this could change with more research being published.

DIAGNOSTICS (2021)

Add to Collection

Review Neurosciences

Rodent Models to Analyze the Glioma Microenvironment

Susann Hetze et al.

Summary: Animal models are crucial for studying glioma development and invasion, with preclinical approaches helping to assess treatment efficacy of new drugs. The tumor microenvironment has been recognized as a key player in the nature of glioma, and available rodent models are evaluated for their usability in researching the glioma microenvironment.

ASN NEURO (2021)

Add to Collection

Article Medicine, General & Internal

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Enli Liu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Clinical Neurology

Decreased natural killer cells in diffuse intrinsic pontine glioma patients

Lei Zhang et al.

CHILDS NERVOUS SYSTEM (2020)

Add to Collection

Review Biology

Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies

Ana Rita Pombo Antunes et al.

ELIFE (2020)

Add to Collection

Review Biochemistry & Molecular Biology

The Role of Selected Chemokines and Their Receptors in the Development of Gliomas

Magdalena Groblewska et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Add to Collection

Article Oncology

Repolarized macrophages, induced by intermediate stereotactic dose radiotherapy and immune checkpoint blockade, contribute to long-term survival in glioma-bearing mice

Alexander M. Stessin et al.

JOURNAL OF NEURO-ONCOLOGY (2020)

Add to Collection

Article Oncology

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma The CheckMate 143 Phase 3 Randomized Clinical Trial

David A. Reardon et al.

JAMA ONCOLOGY (2020)

Add to Collection

Review Immunology

Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma

Syreeta DeCordova et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Oncology

Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy

Nicole A. P. Lieberman et al.

NEURO-ONCOLOGY (2019)

Add to Collection

Article Biochemistry & Molecular Biology

Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma

Kurt A. Schalper et al.

NATURE MEDICINE (2019)

Add to Collection

Article Biochemistry & Molecular Biology

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

Timothy F. Cloughesy et al.

NATURE MEDICINE (2019)

Add to Collection

Article Oncology

Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma

Mark W. Kieran et al.

NEURO-ONCOLOGY (2019)

Add to Collection

Review Oncology

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

Filipe Martins et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2019)

Add to Collection

Review Engineering, Biomedical

Model systems for studying the blood-brain barrier: Applications and challenges

Sadhana Jackson et al.

BIOMATERIALS (2019)

Add to Collection

Article Multidisciplinary Sciences

Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice

Matthias Mulazzani et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)

Add to Collection

Article Biotechnology & Applied Microbiology

被撤回的出版物: CXCL8 Promotes Glioma Progression By Activating The JAK/STAT1/HIF-1 alpha/Snail Signaling Axis (Retracted article. See vol. 16, pg. 211, 2023)

Zhiming Chen et al.

ONCOTARGETS AND THERAPY (2019)

Add to Collection

Review Immunology

CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy

Michael C. Burger et al.

FRONTIERS IN IMMUNOLOGY (2019)

Add to Collection

Article Oncology

New therapeutic perspectives to manage refractory immune checkpoint-related toxicities

Filipe Martins et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Oncology

Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma

Kevin Bielamowicz et al.

NEURO-ONCOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

S. L. Maude et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Cell Biology

Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade

Adel Samson et al.

SCIENCE TRANSLATIONAL MEDICINE (2018)

Add to Collection

Article Multidisciplinary Sciences

Newcastle disease virus enhances the growth-inhibiting and proapoptotic effects of temozolomide on glioblastoma cells in vitro and in vivo

Yang Bai et al.

SCIENTIFIC REPORTS (2018)

Add to Collection

Review Oncology

Harnessing the immune system in glioblastoma

Nicholas F. Brown et al.

BRITISH JOURNAL OF CANCER (2018)

Add to Collection

Review Oncology

The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity

Jan P. Boettcher et al.

TRENDS IN CANCER (2018)

Add to Collection

Article Oncology

Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2 thorn Breast Cancer Metastasis to the Brain

Saul J. Priceman et al.

CLINICAL CANCER RESEARCH (2018)

Add to Collection

Review Oncology

Adult Glioblastoma

Brian M. Alexander et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Review Medicine, Research & Experimental

Immune microenvironment of gliomas

Anna Gieryng et al.

LABORATORY INVESTIGATION (2017)

Add to Collection

Article Oncology

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller et al.

LANCET ONCOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

S. S. Neelapu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Cell Biology

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

Donald M. O'Rourke et al.

SCIENCE TRANSLATIONAL MEDICINE (2017)

Add to Collection

Article Oncology

The Sequence of Delta24-RGD and TMZ Administration in Malignant Glioma Affects the Role of CD8+T Cell Anti-tumor Activity

Anne Kleijn et al.

MOLECULAR THERAPY-ONCOLYTICS (2017)

Add to Collection

Article Medicine, Research & Experimental

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

Leonid Cherkassky et al.

JOURNAL OF CLINICAL INVESTIGATION (2016)

Add to Collection

Article Medicine, General & Internal

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

Christine E. Brown et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Review Biochemistry & Molecular Biology

Pathophysiological mechanisms regulated by cytokines in gliomas

Anthos Christofides et al.

CYTOKINE (2015)

Add to Collection

Review Biotechnology & Applied Microbiology

Oncolytic viruses: a new class of immunotherapy drugs

Howard L. Kaufman et al.

NATURE REVIEWS DRUG DISCOVERY (2015)

Add to Collection

Article Cell Biology

The Blood-Brain Barrier

Richard Daneman et al.

COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2015)

Add to Collection

Article Multidisciplinary Sciences

The Evidence of Glioblastoma Heterogeneity

Akio Soeda et al.

SCIENTIFIC REPORTS (2015)

Add to Collection

Review Neurosciences

Gliomas and the vascular fragility of the blood brain barrier

Luiz Gustavo Dubois et al.

FRONTIERS IN CELLULAR NEUROSCIENCE (2014)

Add to Collection

Article Oncology

Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma

Christine Lu-Emerson et al.

NEURO-ONCOLOGY (2013)

Add to Collection

Article Biochemistry & Molecular Biology

EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms

C. A. Del Vecchio et al.

ONCOGENE (2013)

Add to Collection

Article Cell & Tissue Engineering

The Cancer Stem Cell Subtype Determines Immune Infiltration of Glioblastoma

Christoph P. Beier et al.

STEM CELLS AND DEVELOPMENT (2012)

Add to Collection

Review Biochemistry & Molecular Biology

The Antisense Oligonucleotide Trabedersen (AP 12009) for the Targeted Inhibition of TGF-β2

Frank Jaschinski et al.

CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2011)

Add to Collection

Article Biotechnology & Applied Microbiology

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

Richard A. Morgan et al.

MOLECULAR THERAPY (2010)

Add to Collection

Article Oncology

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Roger Stupp et al.

LANCET ONCOLOGY (2009)

Add to Collection

Review Immunology

Functions of natural killer cells

Eric Vivier et al.

NATURE IMMUNOLOGY (2008)

Add to Collection

Article Oncology

Impact of radiation therapy on the oncolytic adenovirus dl520:: Implications on the treatment of glioblastoma

Alexa Bieler et al.

RADIOTHERAPY AND ONCOLOGY (2008)

Add to Collection

Article Hematology

A(2A) receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells

Paul E. Zarek et al.

BLOOD (2008)

Add to Collection

Article Oncology

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

Eric J. Small et al.

JOURNAL OF CLINICAL ONCOLOGY (2006)

Add to Collection

Article Oncology

Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.

PE Fecci et al.

CANCER RESEARCH (2006)

Add to Collection

Article Clinical Neurology

Dexamethasone-induced abolition of the inflammatory response in an experimental glioma model: a flow cytometry study

B Badie et al.

JOURNAL OF NEUROSURGERY (2000)

Add to Collection

Hallmarks of the Tumour Microenvironment of Gliomas and Its Interaction with Emerging Immunotherapy Modalities

Related references

Export Citation

Share Paper